ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ADMA BIOLOGICS, INC. Exhibit
EX-99.1 2 e617542_ex99-1.htm       ADMA Files Biologics License Application For Its Third Plasma Collection Center   ADMA BioCenters’ Newest Facility Commences Operations to Further Supplement Supply of Internally-Sourced Donor Plasma for Commercial Products and Pipeline of Hyperimmune IG Candidates   RAMSEY,…
To view the full exhibit click here

About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.